- Home
- RARE vs HTFL Comparison
RARE vs HTFL Comparison
Compare RARE & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RARE | HTFL |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | RARE | HTFL |
|---|---|---|
| Price | $23.86 | $30.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 5 |
| Target Price | ★ $59.95 | $38.20 |
| AVG Volume (30 Days) | ★ 1.7M | 1.2M |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $673,000,000.00 | N/A |
| Revenue This Year | $13.12 | $27.66 |
| Revenue Next Year | $37.80 | $23.55 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.13 | N/A |
| 52 Week Low | $18.29 | $20.13 |
| 52 Week High | $40.17 | $41.22 |
Technical Indicators
Market Signals| Indicator | RARE | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 54.67 | 61.00 |
| Support Level | $20.11 | $28.86 |
| Resistance Level | $25.70 | $32.52 |
| Average True Range (ATR) | 1.07 | 1.56 |
| MACD | 0.06 | 0.31 |
| Stochastic Oscillator | 40.78 | 65.40 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
About HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.